Free Trial

AbCellera Biologics Q3 2023 Earnings Report

AbCellera Biologics logo
$2.81 +0.02 (+0.72%)
(As of 12:28 PM ET)

AbCellera Biologics EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

AbCellera Biologics Revenue Results

Actual Revenue
$6.60 million
Expected Revenue
$11.92 million
Beat/Miss
Missed by -$5.32 million
YoY Revenue Growth
N/A

AbCellera Biologics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

AbCellera Biologics Earnings Headlines

AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up - Still a Buy?
Vacuum up cash with these special trades?
Have you ever heard about a “volatility vacuum?” Most people haven’t. It all revolves around this formula right here. Now, the most important thing is that this equation — when applied to certain tickers at a certain time each month —- can trigger these “volatility vacuums.” And when that happens, anyone has the shot at sucking out payouts of $290, $350, even $1,350 in as little as 24 hours. (With just a $1k starting stake!) Granted, there were smaller wins and those that did not work out but best of all, we can know exactly when these opportunities will hit. I’ve used this info to create a Cash Calendar that lays out the precise dates of these payouts.
See More AbCellera Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AbCellera Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AbCellera Biologics and other key companies, straight to your email.

About AbCellera Biologics

AbCellera Biologics (NASDAQ:ABCL) builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

View AbCellera Biologics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings